Principal Investigator
Eric Sicard, MD
Algorithme Pharma Inc
- 4 trials
- 1 compound
Therapeutic focus
- Postherpetic Neuralgia
- Alzheimer's Disease
- Healthy Non-elderly and Elderly Adults
- Parkinson Disease
All trials (4)
| NCT | Phase | Status | Compound | Sponsor |
|---|---|---|---|---|
| NCT05517486 | Phase 1 | Unknown | — | Grace Therapeutics Inc. |
| NCT05363293 | Phase 1/2 | Completed | AL001 (lithium–salicylate–L-proline) | Alzamend Neuro, Inc. |
| NCT01533077 | Phase 1 | Completed | — | Bial - Portela C S.A. |
| NCT01533116 | Phase 1 | Completed | — | Bial - Portela C S.A. |
Compounds studied
Trial sites (3)
- Decatur, Georgia, United States
- Mount Royal, Quebec, Canada
- Montreal, Canada
Investigator and site data mirrored fromClinicalTrials.gov (public domain).